A prostate-specific membrane antigen-targeted nanoplatform for synergistic prostate cancer therapy through androgen receptor transcriptional repression and self-reinforcing chemodynamic pathway
Androgen receptor (AR) represents a pivotal molecular target in prostate cancer (PCa), rendering hormonal therapy a central role in clinical management. However, limited therapeutic efficacy is frequently observed due to AR overexpression, aberrant splicing, and metabolic reprogramming-mediated drug resistance. Herein, this study constructs MnS-GUL-CB839 (MGC) nanoplatform, which achieves efficient and targeted accumulation in PCa via active-targeting motif Glu-urea-Lys, potently downregulates the expression of AR and its splice variant AR-V7 , and reverses glutamine dependence. In acidic tumor microenvironment, MGC enables sustained release of manganese ions (Mn 2+ ), hydrogen sulfide (H 2 S) and the glutamine metabolism inhibitor CB839. Specifically, Mn 2+ represses transcription of AR and AR-V7 for AR signaling suppression. In parallel, H 2 S elevates intracellular hydrogen peroxide levels via inhibiting the catalytic activity of catalase, CB839 reverses glutamine addiction and diminishes glutathione production through inhibition of the rate-limiting enzyme in glutamine metabolism termed glutaminase 1. H 2 S and CB839 synergistically amplify Mn 2+ -catalyzed Fenton-like reactions, generating abundant hydroxyl radicals. Ultimately, this cascade realizes enhanced chemodynamic therapy (CDT) for ferroptosis and apoptosis induction. In summary, our findings underscore MGC as a promising nanoplatform to integrate AR signaling suppression, metabolic reprogramming and self-enhanced CDT, which establishes a unified therapeutic paradigm for PCa.
Authors
- Jialin Meng (ORCID: https://orcid.org/0000-0002-4622-833X)
- Jun Zhou (ORCID: https://orcid.org/0000-0002-1807-2606)
- Xiao Jun Sun (ORCID: https://orcid.org/0000-0001-6506-1574)
- Guowen Jiang
- Li Zhang (ORCID: https://orcid.org/0000-0003-2599-952X)
- Wanqing Yang (ORCID: https://orcid.org/0009-0009-6607-0996)
- Rui Tan
- Zhaoxu Shi
- Yunjiao Zhang (ORCID: https://orcid.org/0000-0002-6465-7488)
- Wenrui Guan
- Wanshui Yang
- Chaozhao Liang
- Liya Tian
Institutions
- Anhui Medical University (CN)
- Shandong Tumor Hospital (CN)
- First Affiliated Hospital of Anhui Medical University (CN)
- Shandong First Medical University (CN)
- South China University of Technology (CN)
Publication Details
- Journal
- Bioactive Materials
- Published
- 2026-11-19
- DOI
- https://doi.org/10.1016/j.bioactmat.2026.10.036
- Primary Topic
- Nanoplatforms for cancer theranostics
- Type
- article
- Field-Weighted Citation Impact
- 0.00